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Objectives: To determine the predictive value of quantitative evaluation of
myocardial viability on changes in left ventricular function, exercise capacity,
and quality of life after coronary artery bypass grafting in patients with
ischemic heart failure (congestive heart failure, New York Heart Association
class >2 III) with and without angina. Methods: Thirty-five patients, 14 with
congestive heart failure and angina (CHF-angina) and 21 with congestive heart
failure without angina (CHF–no angina) were studied at baseline and 6
months after coronary bypass grafting. Left ventricular function was evaluated
with transthoracic echocardiography and radionuclide ventriculography. Myo-
cardial viability was assessed with [18F]-2-fluoro-2-deoxy-D-glucose using
positron emission tomography. Peak aerobic capacity (peak oxygen consump-
tion) and anaerobic threshold were assessed with treadmill exercise test and
quality of life with a questionnaire. Results: A total of 286 of 336 dysfunctional
left ventricular segments were viable. There were two perioperative deaths
(5.7%) and three late deaths. Left ventricular ejection fraction increased from
23% 6 7% to 32% 6 9% (p < 0.0001), and a linear correlation was found
between the number of viable segments and the changes in ejection fraction
(r 5 0.65; p 5 0.0001). Receiver operating characteristics curve identified eight
viable segments as the best predictor for increase of ejection fraction more
than 5 percentage points. Peak oxygen consumption increased from 15 6 4 to
22 6 5 ml/kg per minute (p < 0.0001). Preoperatively, anaerobic threshold was
identified in one patient from the CHF-angina group and in all from the
CHF–no angina group and increased from 13 6 4 to 19 6 4 ml/kg per minute
(p < 0.0001). Quality of life scores improved significantly in both groups. No
correlation was found between the amount of viable dysfunctional myocardium
and changes in exercise capacity or quality of life. Conclusions: In patients with
postischemic congestive heart failure the amount of viable myocardium
dictates the degree of improvement in left ventricular function after revascu-
larization. (J Thorac Cardiovasc Surg 1998;115:791-9)
Congestive heart failure (CHF) affects 1% to 2%of the adult population in industrialized coun-
tries1 with high cost for health care organizations.
The introduction of angiotensin converting enzyme
(ACE) inhibitors achieved some improvement in
prognosis,2 but the impact on exercise tolerance3
and quality of life4 has been limited.
Coronary artery disease (CAD) is the most com-
mon cause of CHF5 and is associated with a worse
prognosis than other causes.6 However, in patients
with CAD, impairment of left ventricular (LV)
function is not always irreversible. Dysfunctional
myocardial segments subtended by stenotic coro-
nary arteries may recover contractile function after
revascularization and the presence of this “hibernat-
ing” myocardium7 can be predicted by noninvasive
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techniques such as positron emission tomography
(PET), thallium-201 scintigraphy, and dobutamine
echocardiography.8 The phenomenon of myocardial
hibernation raises the possibility that patients with
CAD and CHF may gain functional and prognostic
benefit from coronary artery bypass grafting
(CABG). Although the randomized trials of coro-
nary artery surgery and registry data demonstrated
the symptomatic and prognostic benefit of CABG in
patients with angina or exercise-induced isch-
emia,9, 10 registry data suggested no prognostic ben-
efit of surgery in patients with predominant symp-
toms of heart failure.9 More recently, it has been
shown that surgical revascularization of hibernating
myocardium can result in improved ejection fraction
(EF) even in patients with severe impairment of LV
function.11, 12 In the absence of angina or exercise-
induced ischemia, selection of patients in whom
ventricular function is most likely to improve after
CABG remains difficult, and the effect of revascu-
larization on the clinical status and functional ca-
pacity of patients with CHF is unclear. In these
patients the amount of viable myocardium necessary
to produce clinically meaningful improvements in
LV function and symptomatic status after CABG to
balance the known high operative risk is not known.
The aim of this study was to determine the
predictive value of quantitative evaluation of myo-
cardial viability on changes in ventricular function,
exercise capacity, and quality of life after CABG in
Table I. Characteristics of study patients
Baseline Follow-up
Patient Age Sex Symptoms NYHA CCS LVEF (%) DS VDS PVO2* NYHA CCS LVEF (%) PVO2*
1 49 M HF 4 17 14 14 13.3* 1 24 21.5*
2 57 M HF 3 23 15 13 21* 1 38 16*
3 54 M HF 3 30 10 9 15.4* 1 42 24.4*
4 59 M HF 3 26 15 15 17* 1 56 35*
5 66 M HF 4 21 11 11 — 2 32 —
6 50 M HF 3 37 10 6 16.7* 1 38 19.2*
7 50 M HF 4 30 13 13 20.9* 2 41 23.7*
8 68 M HF 3 15 7 7 12.2* 1 21 27.8*
9 50 M HF 3 21 13 13 12.3* 2 23 20.2*
10 48 M HF 4 19 10 9 12.1* 2 25 19*
11 65 F HF 3 37 9 8 7.4* 2 40 18.4*
12 63 M HF 3 20 12 12 17.2* 1 28 19*
13 57 M HF 3 22 14 13 7.3* 1 37 18*
14 66 M HF 3 21 7 7 20* 2 25 17*
15 72 F HF 3 19 16 15 13.3* 2 26 15.5*
16 57 M HF 3 25 14 14 12.8* 2 — 17.3*
17 62 M HF 4 10 13 13 6.4* 1 29 20.7*
18 66 M HF 3 22 15 15 22* 1 36 24*
19 65 M HF 3 18 15 12 9.7* 2 24 21.7*
20 59 M HF 3 26 15 14 15* 1 38 23.5*
21 59 M HF 3 25 9 8 12.7* 1 39 20.7*
22 41 F A 1 HF 3 2 37 12 5 15 1 1 29 21*
23 55 F A 1 HF 3 3 27 10 10 21.8* 2 2 29 37*
24 68 M A 1 HF 3 2 25 9 4 10 2 1 18 20.5*
25 45 M A 1 HF 3 2 32 9 9 19.3 1 1 54 22.6*
26 53 M A 1 HF 3 2 35 4 0 19.5 1 1 35 33*
27 65 M A 1 HF 3 3 23 12 0 18.3 2 1 22 22.4*
28 63 M A 1 HF 3 2 20 10 10 17.7 1 1 25 15*
29 48 M A 1 HF 3 2 32 7 4 14.3 1 1 33 26*
30 49 M A 1 HF 3 3 35 7 3 14.5 1 1 36 22*
31 62 M A 1 HF 4 3 14 12 0 17 — — — —
32 70 M A 1 HF 4 3 15 13 13 12 — — — —
33 59 M A 1 HF 3 2 20 9 4 17.5 — — — —
34 62 M A 1 HF 3 2 14 13 6 11 — — — —
35 59 M A 1 HF 3 3 15 14 0 12 — — — —
M, Male; F, female; A, angina; HF, heart failure; NYHA, New York Health Association class; CCS, Canadian Cardiovascular Society angina class; DS,
dysfunctional segments; VDS, viable dysfunctional segments; PVO2, Peak VO2(*): Anaerobic threshold attained; LVEF, left ventricular ejection fraction.
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a group of patients with CAD and clinical heart
failure with and without angina.
Methods
Patient population. The patients for this study were
recruited from those referred to our hospital for investi-
gation of heart failure or consideration for CABG or
heart transplantation. Inclusion criteria were chronic ($ 6
months) heart failure (New York Heart Association
[NYHA] class $ III), sinus rhythm, multivessel CAD,
impaired LV systolic function, with at least one dysfunc-
tional LV wall subtended by a stenotic coronary artery
amenable to operative revascularization. Exclusion crite-
ria were myocardial infarction within 6 months, decom-
pensation of heart failure within 3 months, the presence of
more than moderate mitral valve regurgitation as assessed
by transthoracic echocardiography, and the presence of
LV aneurysm. Over an 18-month period 39 consecutive
patients (35 male and 4 female, mean age 58 6 7 years;
range 41 to 72 years) met the entry criteria. On the basis
of the patients’ limiting symptoms and the findings of the
treadmill exercise test, two groups were identified: CHF-
angina—14 patients with symptoms of heart failure and
effort angina; CHF–no-angina—25 patients with symp-
toms of heart failure but no angina. CABG was performed
in all the 14 patients from the CHF-angina group irre-
spective of the viability study findings and in 21 of 25
patients from the CHF–no-angina group. Four patients in
the latter group, in whom no evidence of viability could be
demonstrated by PET, did not undergo CABG and un-
derwent cardiac transplantation or continued medical
treatment. Thus 35 patients constitute the population of
this study (Table I).
All 35 patients had experienced at least one myocardial
infarction (range 1 to 3), and the mean time of the most
recent was 30 6 14 months (range 12 to 60 months) before
the study period. Eleven patients had diabetes (four had
insulin-dependent diabetes), and five patients had a his-
tory of hypertension. The preoperative electrocardiogram
(ECG) showed Q-wave infarction in at least one myocar-
dial territory in all the patients (two territories in nine
patients). All patients were receiving maximal medical
therapy for heart failure, including ACE inhibitors (35),
diuretics (25), and digoxin (7) at the time of recruitment.
The patients from the CHF-angina group were also
receiving antianginal treatment, including nitrates (14)
and calcium channel blockers (3). One patient had a
permanent pacemaker but was in sinus rhythm at the time
of recruitment (patient 16, Table I).
The study was approved by the local ethics committee
and written informed consent was obtained from all the
patients before the study. The radiation exposure was
licensed by the UK Administration of Radioactive Sub-
stances Advisory Committee.
Study protocol. Selective coronary arteriography was
performed in all patients. Patients underwent cardiopul-
monary exercise testing, echocardiography, PET imaging
with [18F]-2-fluoro-2-deoxy-D-glucose (FDG) and radio-
nuclide ventriculography (MUGA) within 4 weeks before
CABG. Echocardiography, MUGA scanning, and tread-
mill exercise testing were repeated 6 months after the
operations. Quality of life was assessed by a self-adminis-
tered questionnaire before and 6 months after operation.
Fig. 1. Correlation between the number of viable dys-
functional LV segments and the absolute changes in
LVEF (d-EF). The equation for this relationship is Y 5
1.2X 1 –3.97.
Fig. 2. Comparison of number of viable dysfunctional LV
segments in patients with changes in LVEF (d-EF) . 5
percentage points and those with # 5 percentage points or
deterioration.
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All medical therapy with the exclusion of nitrates was
withdrawn on the study day both at baseline and follow-
up.
Cardiopulmonary exercise testing. Symptom-limited
cardiopulmonary exercise test was performed using a
treadmill according to a modified Naughton protocol.
Breath-by-breath ventilatory and gas exchange data were
measured using a Morgan Benchmark system (PK Mor-
gan Ltd, Gillingham, UK). Peak oxygen consumption
(VO2) was calculated as the mean of the values recorded
during 30 seconds before peak exercise.13 Attainment of
the anaerobic threshold was assessed as the point at which
carbon dioxide (VCO2) increases disproportionately to
VO2 (v-slope method).
14 The respiratory exchange ratio at
peak exercise was calculated as the ratio VCO2/VO2.
Exercise tests were supervised by a physician unaware of
the patients’ clinical details to avoid bias.
Echocardiography. Segmental LV wall motion was as-
sessed by transthoracic echocardiography (HP Sonos
2500, Hewlett-Packard Company, Andover, Mass.) ac-
cording to the recommendations of the American Society
of Echocardiography.15 To circumvent the problem of
postoperative paradoxical septal movement, wall thicken-
ing was primarily used for the assessment of septal
segments. The wall motion was graded as 1 (normal), 2
(hypokinetic), 3 (akinetic), and 4 (dyskinetic). The wall
motion score index (WMSI) was calculated as the sum of
the scores of the left ventricular segments divided by the
number of segments evaluated.15 A segment was consid-
ered recovering contractile function after CABG if there
was a reduction of at least one point in the wall motion/
systolic thickening score. The echo images were analyzed
by two independent observers blinded to the clinical
details and viability details of the patients. In a random
subset of 10 patients (160 segments), the interobserver
and the intraobserver agreement was assessed using the
kappa agreement test: interobserver k 5 0.82 (95%
confidence interval 0.69 to 0.95); intraobserver k 5 0.90
(95% confidence interval 0.80 to 1.00).
PET. The study for the measurement of myocardial
glucose uptake was carried out during hyperinsulinemic
euglycemic clamp with the glucose analog FDG as de-
scribed previously.16 Images were resliced in the short axis
view, and the LV was divided to provide 16 regions of
interest comparable to the ones used for echocardiographic
analysis.15 A dysfunctional segment was considered viable if
FDG uptake was $ 0.25 mmol/min per gram.17
MUGA. All patients underwent radionuclide ventricu-
lography for the assessment of LVEF.16 Analysis was
performed by two independent physicians blinded to
clinical details including the preoperative or postoperative
status. The interobserver and intraobserver agreement
was assessed in a random subset of 10 patients by means
of a standard method.18 The mean of the differences in EF
was 0.05 6 1.5 percentage points and the 95% limits of
agreement were –2.9% to 3%. An improvement in
LVEF . 5 percentage points (recognized variability in
calculating EF with MUGA) was considered significant.
Quality of life assessment. Quality of life was assessed
with the self-administered Minnesota Living with Heart
Failure Questionnaire,4 which assesses the patient’s per-
ception of how his or her emotional and physical status is
impaired by heart failure. Increasing scores relate to the
severity of impairment, the maximum total score being
105. The physical and emotional impact of heart failure
can also be deduced.19 The baseline reliability of the
questionnaire was assessed by a second self-administra-
tion after an interim period of 7 to 14 days and the
agreement between baseline scores was 0.90 (95% confi-
dence interval 0.86 to 0.95) (weighted kappa).
CABG. Surgery was performed by one surgeon (R.S.B.)
By use of cardiopulmonary bypass, mild hypothermia (32°
to 34° C), and intermittent ischemic arrest.
Statistical analysis. Continuous data are expressed as
mean 6 1 standard deviation. Comparison of paired data
was made with paired t test. Categorical data were com-
pared with the x2 or Fisher’s exact test as appropriate.
Simple linear regression analysis with Pearson’s correla-
tion coefficient was performed to investigate the relation-
ship between two continuous variables. The univariate
association between death and the potential predictors
was assessed with the Fisher’s exact test, unpaired t test, or
Mann-Whitney U test as appropriate and with univariate
logistic regression. Stepwise logistic regression was then
performed, including predictors with p values not greater
than 0.05 in the univariate analysis, and keeping predic-
tors with p values not greater than 0.05 in the multivariate
model. Receiver operator characteristics (ROC) curve
was derived according to the method described by Metz.20
The univariate association between the improvement in
LVEF in excess of 5 percentage points and the potential
predictors was assessed with Fisher’s exact test.
Results
Surgery and clinical outcome. The mean number
of grafts per patient was three and all received a left
Fig. 3. ROC curve demonstrating the sensitivity-specific-
ity pairs for the number of PET-viable segments required
to obtain improvements in LVEF greater than 5 percent-
age points after CABG. The arrow indicates the operator
point associated with the best tradeoff between sensitivity
(88%) and specificity (75%). The area fitted under the
curve is 75% (trapezoid rule).
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internal thoracic artery graft to the left anterior
descending coronary artery. The mean cardiopul-
monary bypass time was 50 6 16 minutes (range 12
to 88 minutes), and the mean aortic crossclamp time
was 24 6 7 minutes (range 6 to 39 minutes). There
were two deaths (patients n 5 31 and n 5 32, Table
I) caused by myocardial failure during the perioper-
ative period (overall perioperative/30 day mortality
5.7%). In the remaining patients there was no
evidence of new myocardial infarction according to
clinical and electrocardiogram (ECG) criteria. Two
patients received inotropic support, and one patient
required intraaortic balloon counterpulsation after
operation. The mean intensive care unit stay was
1.5 6 1.3 days (range 1 to 5 days). Two patients
(5.7%) had transient neurologic dysfunction de-
velop, which resolved without long-term sequelae.
Three patients had postoperative atrial fibrillation
develop requiring direct-current cardioversion,
which resulted in restoration of sinus rhythm. The
medical therapy for heart failure was maintained
unchanged throughout the study period with the
exception of diuretics, the dose of which was re-
duced in eight patients. Antianginal medications
(nitrates and calcium-channel blockers) were with-
drawn at the time of CABG, and no patient required
antianginal treatment after CABG. No patient at-
tended cardiac rehabilitation before the follow-up
investigations. There were three late sudden deaths
before the follow-up study at 2, 3, and 3 months
postoperatively (patients 33, 34, and 35, Table I).
Death occurred out of the hospital, and no postmor-
tem examination was performed. The remaining 30
patients underwent a follow-up study 6 months after
CABG. One patient required hospital admission 4
weeks after CABG for exacerbation of heart failure
symptoms caused by atrial fibrillation; elective di-
rect-current cardioversion was done and long-term
treatment with amiodarone was prescribed. The
NYHA class and the Canadian Cardiovascular So-
ciety angina class improved in all patients (Table I).
Factors predictive of mortality. Five deaths oc-
curred in the study group (two perioperative and
three before follow-up study); thus the 6-month
actuarial survival was 86%. Univariate analysis iden-
tified low LVEF (p 5 0.002), small number of
dysfunctional viable segments (p 5 0.02), and low
percentage of viable dysfunctional myocardium
(number viable dysfunctional/total number dysfunc-
tional segments 3 100) (p 5 0.02) as factors asso-
ciated with early death (perioperative and before
follow-up), whereas age, sex, NYHA class, peak
Fig. 4. Exercise data for CHF–no-angina patients. An-
aerobic threshold was achieved in all cases at baseline and
at the follow-up study. The respiratory exchange ratio at
peak exercise before CABG was 1.12 6 0.07 and 1.1 6
0.07 at follow-up. Heart rate at peak exercise was 129 6 29
beats/min before CABG and 137 6 18 beats/min at
follow-up (p 5 0.09). 95% CI 5 95% confidence interval
of the mean change.
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VO2, and exercise time were not predictive. Stepwise
logistic regression identified low LVEF (p 5 0.03)
and low percentage of viable dysfunctional myocar-
dium (p 5 0.03) equally as predictors of early death.
Myocardial viability. A total of 453 LV segments
could be assessed by both echocardiography and
PET, and 425 (94%) of these were revascularized.
Of these, 89 (21%) had normal wall motion and 336
(79%) were dysfunctional (180 hypokinetic and 156
akinetic). The mean number of dysfunctional seg-
ments per patient was 11 6 3 (range 7 to 15). The
FDG uptake was significantly higher in the hypoki-
netic than in the akinetic segments (0.43 6 0.16 vs
0.38 6 0.15 mmol/min per gram; p 5 0.003). A total
of 286 (85%) dysfunctional segments were PET
viable (i.e., had FDG uptake $ 0.25 mmol/min per
gram). Viability was detected in 167 of 180 (93%)
hypokinetic and in 123 of 156 (79%) akinetic seg-
ments (p 5 0.004). The mean number of PET viable
segments per patient was 9 6 4 (range 0 to 15). Of
these, 190 out of 286 segments (90 hypokinetic and
100 akinetic) had improved wall motion after
CABG (positive predictive value 66%). Forty-eight
of the 50 dysfunctional segments that were deemed
nonviable (FDG uptake # 0.25 mmol/min per gram)
did not have improved wall motion after operation
(negative predictive value 96%). In 12 out of 425
revascularized segments (9 normal and 3 dysfunc-
tional) (2.5%) wall motion worsened after CABG.
The percentage of PET viable myocardium was less
in the CHF-angina group (45 of 80 [56%] dysfunc-
tional segments) than in the CHF–no angina group
(241 of 257 [94%]).
Changes in LV function. The mean baseline ra-
dionuclide LVEF was 23% 6 7%. The patient with
a pacemaker (patient 16, Table I) was excluded from
the follow-up radionuclide ventriculography be-
cause during this study he manifested a predomi-
nant ventricular paced rhythm. In the remaining 29
patients there was a significant increase in mean
LVEF to 32% 6 9% (95% confidence interval of
the change 4.3% to 11%; p , 0.0001) after revascu-
larization. LVEF changed from 29% 6 6% to 31%
6 10% (p 5 0.58) in the CHF-angina group and
from 23% 6 7% to 33% 6 8% (p , 0.0001) in the
CHF–no angina group. There was a significant
reduction in the mean WMSI from 2.18 6 0.3 to
1.7 6 0.3 (95% confidence interval of the mean
change: –0.6 to –0.3; p , 0.0001), and a linear
correlation was found between the reduction (im-
provement) in WMSI and EF changes (r 5 –71, p ,
0.0001). A linear correlation was found between the
number of dysfunctional segments with FDG up-
take $ 0.25 mmol/min per gram in each patient
(PET-viable segments) and the changes in EF (Fig.
1). The 17 patients with EF improvement . 5
percentage points had more dysfunctional viable
segments compared with the 12 patients with less or
no improvement (Fig. 2). ROC analysis identified
eight viable segments as the discriminator to iden-
tify . 5 percentage points improvement in EF (Fig.
3).
Changes in exercise capacity. One patient with
left main CAD did not undergo preoperative exer-
cise testing (patient 5, Table I). In CHF-angina
patients exercise was discontinued because of a
combination of chest pain and dyspnea and in those
from the CHF–no angina group because of dyspnea
and fatigue without ECG evidence of ischemia. An
anaerobic threshold was identified in all 20 patients
from CHF–no angina and in 1 of 9 patients from
CHF-angina group. The exercise data are shown in
Table II and Fig. 4. The number of viable dysfunc-
tional segments and the changes in LVEF did not
correlate with any exercise parameters.
Quality of life scores. Quality of life scores im-
proved in all the patients (Table III).
Discussion
In this study, the amount of viable dysfunctional
myocardium predicted the extent of LV functional
improvement in patients with CHF after CABG.
Objective improvements in exercise performance
and quality of life scores occurred but did not
correlate with the amount of viable dysfunctional
myocardium. The presence of angina was not always
Table II. Exercise test data on all and CHF-angina patients
All patients CHF-angina patients
Baseline Follow-up 95% CI p Value Baseline Follow-up 95% CI p Value
Peak VO2 (ml/kg/min) 15 6 4 22 6 5 4.9-9.3 ,0.0001 16 6 4 24 6 5 3.3-12 ,0.0001
Exercise time (sec) 439 6 215 718 6 227 204-354 ,0.0001 480 6 215 756 6 195 133-419 ,0.0001
Heart rate (peak exercise) bpm 126 6 20 141 6 16 6-22 0.0008 118 6 15 143 6 10 9-39 0.003
95% CI, 95% Confidence interval of the mean change.
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associated with viability but lack of angina did not
preclude objective improvements in LVEF or exer-
cise tolerance. The relief of angina after CABG
improved exercise tolerance irrespective of the
amount of viable myocardium.
Mortality. Severity of LV dysfunction is known to
influence the early outcome of CABG particularly if
advanced heart failure is present.21 Although recent
studies have shown low mortality in patients with
low EF undergoing CABG, most patients studied
had angina without heart failure.22, 23 This study
suggests that the extent of viable dysfunctional
myocardium is an important predictor of early death
after CABG when heart failure is present. If this
finding is reproduced in a larger population, the
assessment of viability becomes critical in the eval-
uation of the risk/benefit ratio when considering
operation.
Viability and angina. Significant myocardial via-
bility was detected both in patients with and without
angina, but this symptom was an unreliable predic-
tor of viability. It is known that there is no correla-
tion between the presence of angina and the severity
and extent of CAD or ischemia.24 Viability was
greater in the CHF–no angina group, but a mean-
ingful comparison of the two groups could not be
made because we did not submit patients with no
viability and no angina to CABG. Although there
was differential recovery of function between
groups, the denominator is small, precluding mean-
ingful comparisons.
LV function. LV functional recovery was related
to the amount of viability. The positive predictive
accuracy of PET imaging for regional LV functional
recovery (66%) was lower than previously reported
in patients with modest LV impairment25 but com-
parable to studies of patients with severe LV dys-
function.11 The reduced accuracy in such patients
may reflect the amount of akinetic segments (46% in
our study) because these may have more advanced
ultrastructural changes than less dysfunctional re-
gions.26 It is possible that such segments require
more time for functional recovery27 and our single 6
months assessment may have underestimated the
amount of improvement. In addition, islands of
myocytes in myocardium with significant subendo-
cardial scarring may be viable but with little pros-
pect of improving resting contractile function after
CABG.28 However, these regions may still improve
on inotropic stimulation and contribute to LV func-
tion on exercise.29 In agreement with a previous
study,11 an improvement in LVEF of greater than 5
percentage points occurred only in patients with
significant viable myocardium. This underlines the
importance of accurate preoperative assessment of
viability particularly in patients with very poor LV
function who have the highest perioperative risk.
Exercise performance. Objective measures of ex-
ercise performance improved in all the patients after
CABG. In the CHF-angina patients, however, fail-
ure to attain anaerobic threshold and the limitation
of exercise by angina do not allow an objective
evaluation of the results. In contrast, all the patients
limited by heart failure symptoms exercised maxi-
mally attaining anaerobic threshold and improved
markedly.
No correlation was found between the changes in
LVEF, viability, and exercise parameters in accor-
dance with other studies,30 and this requires expla-
nation. No data are available relating viability to LV
function during exercise. We have previously ob-
served in a similar cohort of patients that CABG
may be associated with improvement in peak VO2
and LV inotropic contractile reserve without change
in resting LV function.31 Finally, the improvement
in global LV function during exercise may depend
not only on the recruitment of dysfunctional myo-
cardium but also on the relief of exercise-inducible
ischemia in normofunctioning segments.
Quality of life scores. The Minnesota Living with
Heart Failure Questionnaire scores improved in all
the patients. However, whereas in the patients with
angina improvements in quality of life may be
secondary to relief of chest pain, the improvements
in the heart failure patients reflect a genuine im-
provement in heart failure functional status.
Table III. Quality of life scores
All patients CHF-angina patients CHF–no-angina patients
Baseline Follow-up p Value Baseline Follow-up p Value Baseline Follow-up p Value
MLHF 57 6 15 30 6 11 ,0.0001 51 6 4 34 6 6 0.001 59 6 16 29 6 12 ,0.0001
Physical 26 6 5 14 6 7 ,0.0001 22 6 2 15 6 2 ,0.0001 27 6 5 14 6 7 ,0.0001
Emotional 13 6 5 7 6 3 0.0001 10 6 2 6 6 1 0.01 14 6 5 7 6 3 ,0.0001
MLHF, Minnesota Living with Heart Failure questionnaire; Scores are for the entire questionnaire and for the physical and emotional dimensions.
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CABG for congestive cardiac failure. An impor-
tant observation of this study was the assessment of
the effects of CABG in patients with postischemic
cardiomyopathy with no symptoms of angina but
viable dysfunctional myocardium. In these patients
improvements in LV function, exercise capacity, and
quality of life scores were substantial and clearly
superior to those usually obtained by medical treat-
ment.3, 4 To date, CABG has been used mostly to
treat patients with angina or demonstrable ischemia.
The results of this study suggest that CABG may
also have a role in the treatment of severe heart
failure in patients with CAD even in the absence of
angina. Both angina and hibernation are manifesta-
tions of ischemia,16 thus it is not surprising that
coronary revascularization is effective in improving
both conditions. LV function and peak VO2 are
powerful prognostic indicators in heart failure,13
and it is possible that the improvements demon-
strated 6 months after CABG may translate into
prognostic benefit.
Study limitations. We did not compare the ef-
fects of operation with those of continued medical
treatment. Although some retrospective studies9, 22
have attempted this, no study has a truly random-
ized control group and most of the patients treated
in the operated group had angina as a predominant
symptom. In this study all the patients in the
CHF–no angina group had extensive myocardial
viability, and this may be a reflection of the selection
criteria. The role of operation in the management of
patients in the CHF–no angina group with minimal
or absent viable myocardium remains unknown. The
results of this study are encouraging but need cor-
roboration in a larger population.
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technical colleagues at the Queen Elizabeth Hospital,
Birmingham, and the MRC-Cyclotron Unit Hammer-
smith Hospital, London, who contributed to data acquisi-
tion. We are indebted to P. Davies, PhD C.Stat, from the
school of Mathematics and Statistics of the University of
Birmingham for the advice in the statistical analysis of the
data.
R E F E R E N C E S
1. Kannel W, Belanger A. Epidemiology of heart failure. Am
Heart J 1991;121:951-7.
2. CONSENSUS study group. Effects of enalapril on mortality
in severe congestive heart failure: results of the Cooperative
North Scandinavian Enalapril Survival Study. N Engl J Med
1987;316:1429-35.
3. Cohn J, Johnson G, Ziesche S, et al. A comparison of
enalapril with hydralazine-isosorbide dinitrate in the treat-
ment of chronic congestive heart failure. N Engl J Med
1991;325:303-10.
4. Rector T, Johnson G, Dunkman B, et al. Evaluation by
patients with heart failure of the effects of enalapril com-
pared with hydralazine plus isosorbide dinitrate on quality of
life. V-HeFT II. Circulation 1993;87(suppl VI):VI-71-7.
5. SOLVD Investigators. Effect of enalapril on survival in
patients with reduced left ventricular ejection fraction and
congestive heart failure. N Engl J Med 1991;325:293-302.
6. Jessup Likoff M, Chandler S, Kay H. Clinical determinants of
mortality in chronic congestive heart failure secondary to
idiopathic dilated or to ischaemic cardiomyopathy. Am J
Cardiol 1987;59:634-8.
7. Rahimtoola SH. The hibernating myocardium. Am Heart J
1989;117:211-21.
8. Dilsizian V, Bonow RO. Current diagnostic techniques of
assessing myocardial viability in patients with hibernating and
stunned myocardium. Circulation 1993;87:1-20.
9. Alderman E, Fisher L, Litwin P, et al. Results of coronary
artery surgery in patients with poor left ventricular function
(CASS). Circulation 1983;4:785-95.
10. Passamani E, Davies K, Gillespie M, et al. A randomised trial
of coronary artery bypass surgery: survival of patients with
low ejection fraction. N Engl J Med 1985;312:1665-71.
11. vom Dahl J, Eitzman DT, al Aouar ZR, et al. Relation of
regional function, perfusion, and metabolism in patients with
advanced coronary artery disease undergoing surgical revas-
cularization. Circulation 1994;90:2356-66 .
12. Dreyfus G, Duboc D, Blasco A, et al. Myocardial viability
assessment in ischaemic cardiomyopathy: benefits of coro-
nary revascularisation. Ann Thorac Surg 1994;57:1402-8.
13. Cohn J, Rector T. Prognosis of congestive heart failure and
predictors of mortality. Am J Cardiol 1988;62(Suppl):25A-
30A.
14. Wasserman K, Whipp B, Koyal S, Beaver W. Anaerobic
threshold and respiratory gas exchange during exercise.
J Appl Physiol 1973;35:236-43.
15. Segar D, Brown S, Sawada S, Ryan T, Feigenbaum H.
Dobutamine stress echocardiography: correlation with coro-
nary lesion severity as determined by quantitative angiogra-
phy. J Am Coll Cardiol 1992;19:1197-202.
16. Marinho N, Keogh B, Costa D, Lammertsma A, Ell P,
Camici PG. Pathophysiology of chronic left ventricular dys-
function: new insights from the measurement of absolute
myocardial blood flow and glucose utilisation. Circulation
1996;93:737-44.
17. Fath-Ordoubadi F, Marinho N, Keogh B, Pagano D, Costa
D, Camici PG. Value of positron emission tomography in
predicting functional recovery following coronary revascu-
larisation: effect of baseline wall motion score and ejection
fraction [abstract]. Eur Heart J 1995;16(suppl):129.
18. Bland M, Altman D. Statistical methods for assessing agree-
ment between two methods of clinical measurements. Lancet
1986;1(Feb 8):307-10.
19. Rector T, Spencer H, Cohn J. Validity of the Minnesota
Living with Heart Failure Questionnaire as a measure of
therapeutic response to enalapril or placebo. Am J Cardiol
1993;71:1106-7.
20. Metz C. Basic principles of ROC analysis. Semin Nucl Med
1978;8:283-98.
21. Wechsler AS, Junod FL. Coronary bypass grafting in patients
The Journal of Thoracic and
Cardiovascular Surgery
April 1998
7 9 8 Pagano et al.
with chronic congestive heart failure. Circulation 1989;
79(suppl I):I-92-6.
22. Luciani GB, Faggian G, Razzolini R, Livi U, Bortolotti U,
Mazzucco A. Severe ischaemic left ventricular failure: coro-
nary operation or heart transplantation? Ann Thorac Surg
1993;55:719-23.
23. Mickleborough L, Maruyama H, Tagaki T, Mohamed S, Sun
Z, Ebisuzaki L. Results of revascularisation in patients with
severe left ventricular dysfunction. Circulation 1995;92[suppl
II]:ii-73-9.
24. Rosen S, Nihoyannopoulos P, Tousoulis D, Frackowiack R,
Frith C, Jones T, et al. Silent ischaemia as a central problem:
regional brain activation compared in silent and painful
myocardial ischaemia. Ann Intern Med 1996;124:939-49.
25. Bonow R. Identification of viable myocardium. Circulation
1996;94:2674-8.
26. Ausma J, Cleutjens J, Thone´ F, Flameng W, Ramaekers F,
Borges M. Chronic hibernating myocardium: interstitial
changes. Mol Cell Biochem 1995;147:35-42.
27. Vanovershelde J, Melin J, Depre´ C, Borges M, Dion R,
Wijns W. Time course of functional recovery of hibernating
myocardium after coronary revascularisation [abstract]. Cir-
culation 1994;90(Suppl):I378.
28. Armstrong W. “Hibernating” myocardium: asleep or part
dead? J Am Coll Cardiol 1996;28:530-5.
29. Kaul S, There may be more viability than meets the eye!
Circulation 1995;92:2790-3.
30. Franciosa J, Park M, Levine B. Lack of correlation between
exercise capacity and indices of resting left ventricular per-
formance in heart failure. Am J Cardiol 1981;47:33-9.
31. Townend J, Pagano D, Allen S, Jordan P, Davies M, Littler
W, et al. Results of surgical revascularisation in ischaemic
heart failure without angina. Eur J Cardiothorac Surg 1995;
9:507-14.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 4
Pagano et al. 7 9 9
